Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:3382 |
Name | liposarcoma |
Definition | A connective tissue cancer that arises in fat cells in deep soft tissue retroperitoneum and the extremities. |
Source | DiseaseOntology.org |
Alt Ids | DOID:3939 |
Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer liposarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TP53 wild-type | MK-8242 | liposarcoma | predicted - sensitive | detail... |
TP53 wild-type | ALRN-6924 | liposarcoma | predicted - sensitive | detail... |
TP53 wild-type | KRT-232 | liposarcoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00356031 | Phase II | Bevacizumab | Bevacizumab and Radiation Therapy for Sarcomas | Completed | USA | 0 |
NCT01506596 | Phase II | Pazopanib | Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma | Completed | USA | 0 |
NCT02048371 | Phase II | Regorafenib | A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas | Completed | USA | 0 |
NCT02210104 | Phase I | Ipilimumab Cyclophosphamide | Adoptive Therapy Using Antigen-Specific CD4 T-Cells | Withdrawn | 0 | |
NCT02275286 | Phase Ib/II | Trabectedin | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS) | Recruiting | ITA | FRA | ESP | 0 |
NCT02301039 | Phase II | Pembrolizumab | A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas | Completed | USA | 0 |
NCT02343172 | Phase Ib/II | Ribociclib + Siremadlin | Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma | Completed | FRA | ESP | DEU | CAN | 2 |
NCT02357810 | Phase II | Pazopanib + Topotecan | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas | Completed | USA | 0 |
NCT02606461 | Phase II | Selinexor | KCP-330-020 SEAL (Selinexor in Advanced Liposarcoma) (SEAL) | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 2 |
NCT02846987 | Phase II | Abemaciclib | Study of Abemaciclib in Dedifferentiated Liposarcoma | Active, not recruiting | USA | 0 |
NCT02923778 | Phase II | Talimogene laherparepvec | Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery | Active, not recruiting | USA | CAN | 0 |
NCT02978859 | Phase II | Sitravatinib | MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas | Active, not recruiting | USA | 0 |
NCT03009201 | Phase I | Doxorubicin + Ribociclib | Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03074318 | Phase Ib/II | Avelumab + Trabectedin | Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery | Terminated | USA | 0 |
NCT03114527 | Phase II | Everolimus + Ribociclib | Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | Active, not recruiting | USA | 0 |
NCT03190174 | Phase Ib/II | Nab-rapamycin + Nivolumab | Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma | Completed | USA | 0 |
NCT03307616 | Phase II | Ipilimumab + Nivolumab Nivolumab | Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma | Active, not recruiting | USA | 0 |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Terminated | USA | FRA | ESP | DEU | 2 |
NCT03474094 | Phase II | Atezolizumab | Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy (RT-Immune) | Recruiting | GBR | FRA | 0 |
NCT03548428 | Phase II | Atezolizumab | Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc) (Stereosarc) | Recruiting | FRA | 0 |
NCT03719430 | Phase II | APX005M + Doxorubicin + Olaratumab | APX005M, Doxorubicin, Olaratumab in Advanced Sarcoma | Recruiting | USA | 0 |
NCT03860207 | Phase Ib/II | Hu3F8-BsAb | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | Terminated | USA | 0 |
NCT03880123 | Phase I | Ixazomib + Selinexor | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | Withdrawn | USA | 0 |
NCT03899805 | Phase II | Eribulin + Pembrolizumab | A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | Active, not recruiting | USA | 0 |
NCT03964233 | Phase I | BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab BI 907828 | A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With Ezabenlimab With or Without BI 754111 | Recruiting | USA | GBR | FRA | ESP | DEU | BEL | AUS | 4 |
NCT04076579 | Phase II | Olaparib + Trabectedin | Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma | Active, not recruiting | USA | 0 |
NCT04205227 | Phase Ib/II | ENB003 + Pembrolizumab | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT04216953 | Phase Ib/II | Atezolizumab + Cobimetinib | MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma (COTESARC) | Recruiting | FRA | 0 |
NCT04242238 | Phase I | Avelumab + Vimseltinib | Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas | Active, not recruiting | USA | 0 |
NCT04420975 | Phase I | BO-112 + Nivolumab | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT04557449 | Phase I | Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i) | Recruiting | USA | GBR | 6 |
NCT04906876 | Phase II | 9-ING-41 + Docetaxel + Gemcitabine | 9-ING-41Combined With Chemotherapy in Adolescents and Adults | Withdrawn | USA | 0 |
NCT05116800 | Phase II | 9-ING-41 + Docetaxel + Gemcitabine | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | Withdrawn | USA | 0 |
NCT05389462 | Phase I | ADCT-601 + Gemcitabine ADCT-601 | A Dose-Escalation and Dose-Expansion Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | Recruiting | USA | FRA | ESP | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advance Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT06025747 | Phase I | Abemaciclib | Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma | Not yet recruiting | 0 |